Myeloid Lineage Markers
About Myeloid Lineage Markers
Hematopoietic stem cells (HSCs) are capable of differentiating into two major lineages of cells, lymphocytes and myeloid cells. Myeloid lineage cells develop during myelopoiesis and include monocytes, macrophages granulocytes (neutrophils, eosinophils, and basophils), and dendritic cells. Circulating erythrocytes and platelets also develop from myeloid progenitor cells. These cells play a key role in immune responses, including inflammatory responses, antibacterial/antiviral responses, and antitumor activity. Many myeloid cells have a short lifespan, and homeostasis of the immune system requires continuous self-renewal and differentiation of hematopoietic stem cells. Myeloid lineage markers are cell surface molecules or intracellular proteins that act as characteristic identifiers of myeloid lineage cells. These markers play a critical role in identifying and characterizing myeloid cells in research and clinical settings.
Fig.1 Myeloid cell differentiation -Schematic figure of myeloid differentiation including the corresponding leukemia and non-Hodgkin lymphomas as well as cell markers involved in each stage. (Plesa A, et al., 2006)
Functions of Myeloid Lineage Markers
- Cell Identification
Myeloid lineage markers provide a means to identify and distinguish myeloid cells from other cell types in complex cellular populations. By detecting the presence or absence of specific markers, researchers can accurately identify myeloid cells and study their properties.
- Cell Differentiation and Maturation
Myeloid lineage markers are often differentially expressed during different stages of myeloid cell development, differentiation, and maturation. Monitoring the expression of these markers allows researchers to track and analyze the progression of myeloid cell differentiation and functional specialization.
- Immunophenotyping
Myeloid lineage markers are extensively used in immunophenotyping studies to characterize myeloid cell subsets and assess their functional properties. By combining different markers, researchers can create immunophenotypic profiles that provide insights into the heterogeneity and functional diversity of myeloid cells
- Disease Diagnosis and Monitoring
Altered expression patterns of myeloid lineage markers can serve as diagnostic or prognostic indicators for various diseases. Aberrant expression or the presence of specific markers on myeloid cells can be indicative of certain pathological conditions, such as leukemia, myeloproliferative disorders, or inflammatory diseases.
Available Products and Resources of Myeloid Lineage Markers
Myeloid Lineage Markers Products
Creative BioMart offers a wide range of high-quality tools for the study of hematopoietic stem cell differentiation, including recombinant proteins, native proteins, cell & tissue lysates, transfected stable cell lines, protein pre-coupled magnetic beads, chromatography reagents, assay kits, and other types of products. We also offer a range of individual antibodies to study the expression of hematopoietic lineage-specific markers. Many myeloid cells can be identified by analyzing the expression of specific cell surface markers, such as clusters of differentiation (CD) proteins. In addition, differentiated cells such as erythrocytes can be identified by the expression of blood group glycoproteins, and Tpo R is expressed on the surface of megakaryocytes. Creative BioMart offers a wide range of products, services and resources to support research involving myeloid marker related studies. Click to view all related molecules/targets and research reagents.
Our Advantages
We are committed to providing our customers with quality products and services for their research and application needs. If you are interested in our products, services, or resources, please contact us immediately for more information, thank you for your attention!
Reference:
- Plesa A, Ciuperca G, Genieys S, Louvet V, Pujo-Menjouet L, Millaret A, Dumontet C, Volpert V. A Biomathematical Analysis of Immunophenotypic Characteristics in Patients with Acute Myeloblastic Leukemia. (2006): 4487-4487.
